These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12757727)

  • 41. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors.
    Böhm M; Mitsch A; Wissner P; Sattler I; Schlitzer M
    J Med Chem; 2001 Sep; 44(19):3117-24. PubMed ID: 11543680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
    Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
    Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1359-62. PubMed ID: 12657282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
    Roskoski R; Ritchie PA
    Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.
    Bell IM; Gallicchio SN; Abrams M; Beshore DC; Buser CA; Culberson JC; Davide J; Ellis-Hutchings M; Fernandes C; Gibbs JB; Graham SL; Hartman GD; Heimbrook DC; Homnick CF; Huff JR; Kassahun K; Koblan KS; Kohl NE; Lobell RB; Lynch JJ; Miller PA; Omer CA; Rodrigues AD; Walsh ES; Williams TM
    J Med Chem; 2001 Aug; 44(18):2933-49. PubMed ID: 11520202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent, non-thiol inhibitors of farnesyltransferase.
    Breslin MJ; deSolms SJ; Giuliani EA; Stokker GE; Graham SL; Pompliano DL; Mosser SD; Hamilton KA; Hutchinson JH
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3311-6. PubMed ID: 9873725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.
    Tong Y; Lin NH; Wang L; Hasvold L; Wang W; Leonard N; Li T; Li Q; Cohen J; Gu WZ; Zhang H; Stoll V; Bauch J; Marsh K; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 May; 13(9):1571-4. PubMed ID: 12699757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
    Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
    Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B; Prendergast GC; Fenton RG
    Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
    Mitsch A; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.
    Tahir SK; Gu WZ; Zhang HC; Leal J; Lee JY; Kovar P; Saeed B; Cherian SP; Devine E; Cohen J; Warner R; Wang YC; Stout D; Arendsen DL; Rosenberg S; Ng SC
    Eur J Cancer; 2000 Jun; 36(9):1161-70. PubMed ID: 10854950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
    de Figueiredo RM; Coudray L; Dubois J
    Org Biomol Chem; 2007 Oct; 5(20):3299-309. PubMed ID: 17912382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.
    Manne V; Lee FY; Bol DK; Gullo-Brown J; Fairchild CR; Lombardo LJ; Smykla RA; Vite GD; Wen ML; Yu C; Wong TW; Hunt JT
    Cancer Res; 2004 Jun; 64(11):3974-80. PubMed ID: 15173010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
    Dinsmore CJ; Bergman JM; Wei DD; Zartman CB; Davide JP; Greenberg IB; Liu D; O'Neill TJ; Gibbs JB; Koblan KS; Kohl NE; Lobell RB; Chen IW; McLoughlin DA; Olah TV; Graham SL; Hartman GD; Williams TM
    Bioorg Med Chem Lett; 2001 Feb; 11(4):537-40. PubMed ID: 11229765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel metal-chelating inhibitor of protein farnesyltransferase.
    Hamasaki A; Naka H; Tamanoi F; Umezawa K; Otsuka M
    Bioorg Med Chem Lett; 2003 May; 13(9):1523-6. PubMed ID: 12699746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
    Roskoski R; Ritchie P
    Arch Biochem Biophys; 1998 Aug; 356(2):167-76. PubMed ID: 9705207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.